News
From new developments in our team to new introductions in the Dutch medicine market. Read our latest news. Are you already following us on LinkedIn?
19-01-2021
We are pleased to inform you that Prolepha Research B.V. has added Lormetazepam 1mg + 2m to its product range as of February 1 2021. The package leaflet can be found on our product range page. If you have any questions, please contact us using the information provided on our contact page.*ZI-number 16947878, 16947924.
01-01-2021
We are pleased to inform you that Prolepha Research B.V. has added Ezetimibe Aristo 10mg to its product range as of January 1 2021. The package leaflet can be found on our product range page. If you have any questions, please contact us using the information provided on our contact page. *ZI-number 16961757.
01-01-2021
We are pleased to inform you that Prolepha Research B.V. has added 2021 Amoxicilline/clavulaanzuur Aristo 875 mg/ 125 mg to its product range as of January 1 2021. The package leaflet can be found on our product range page. If you have any questions, please contact us using the information provided on our contact page. *ZI-number 16961773.
16-12-2020
We are pleased to inform you that Prolepha Research B.V. has added Salmeterol/Fluticasone Neutec pre-dispensed inhalation powder in the strengths of 50/100mcg, 50/250mcg, and 50/500mcg to its product range. The package leaflet (patient information leaflet) can be found on our product range page. Do you have any further questions? Please contact us using the details found on our contact page. *ZI-number: 16955145, 16961714, 16961722. View the instructional film here to use the inhaler correctly.
12-11-2020
Some time ago, Prolepha introduced amisulpride tablets (brand name Aktiprol®) in the strengths of 50 mg, 100 mg, 200 mg, and 400 mg to the Dutch market. Amisulpride is an antipsychotic, indicated for use in schizophrenia. Amisulpride was initially only available in the Netherlands as a compassionate-use supply (collegial delivery) and as an imported preparation; Prolepha currently offers the first and only registered alternative. We are pleased to announce that amisulpride will be included in the GVS (Drug Reimbursement System) as of December 1st next. As of December 1st, our product will therefore be fully reimbursed for the Dutch patient population.